Meanwhile, these modifications lead to CCA growth, migration, local invasion, and metastatic dissemination, although BMI1 can be potentially utilized as a druggable target by its knockdown as a therapeutic option for several tumors, including CCA [79]. The gene discussed is BMI1; the disease is cholangiocarcinoma.